A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy

  • Patient Population – Patients with orthostatic hypertension associated with PD, MSA, PAF, NDAN or DBH Deficiency, who score a 4 or greater on the Orthostatic Hypotension Symptom Assessment (OHSA.)
  • Study Description - The aim of this study is to evaluate the time to treatment intervention in patients with Parkinson ’s Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy(NDAN) or Dopamine Beta Hydroxylase (DBH)Deficiency who have been previously stabilized with droxidopa therapy for symptoms of neurogenic orthostatic hypotension.
  • Sponsor –   Lundbeck
  • Contact Information –  (402) 384-2705 or by email to see if you qualify.
  • Clinical Trials Government Link
©2018 Heart Consultants P.C. All Rights Reserved